Sponsor or institution
Clinical trials and research at Guangzhou Virotech Pharmaceutical Co., Ltd.
As of November 12, 2026, Find a Trial lists 6 clinical trials run by Guangzhou Virotech Pharmaceutical Co., Ltd. that are recruiting, at sites in 2 countries (most in China (5), Japan (1)). By phase: Phase 1 (3), Phase 2 (1), Phase 1/2 (1), Phase 2/3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 2Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| VRT106 plus radiotherapy in adults with DMG/DIPG | Phase 2 | Guangzhou, Guangdong | Recruiting | May 15, 2026 |
| VRT106 plus camrelizumab and apatinib for advanced HCC in patients who have tried prior ICIs | Phase 2/3 | Guangzhou, Guangdong | Recruiting | May 15, 2026 |
| VRT106 injections for recurrent or progressive glioblastoma. | Phase 1/2 | Hefei, Anhui and 10 other locations | Recruiting | Jul 30, 2025 |
| Intravenous VRT106 for locally advanced or metastatic solid tumors | Phase 1 | Guangzhou, Guangdong | Recruiting | Feb 13, 2025 |
| Using a virus to treat solid tumors | Phase 1 | Guangzhou, Guangdong and 2 other locations | Recruiting | Apr 16, 2024 |
| Treatment of advanced solid tumors with intravenous M1-c6v1 | Phase 1 | Kashiwa-shi, Chiba and 2 other locations | Recruiting | Sep 21, 2023 |
All recruiting trials (6)
-
VRT106 plus radiotherapy in adults with DMG/DIPG
This trial tests whether adding VRT106 to radiotherapy is safe and could help adults with DMG/DIPG.
-
VRT106 plus camrelizumab and apatinib for advanced HCC in patients who have tried prior ICIs
This study tests VRT106, with camrelizumab and apatinib, to see if it helps people with advanced hepatocellular carcinoma who have already had prior immune checkpoint inhibitors fail.
-
VRT106 injections for recurrent or progressive glioblastoma.
This trial will test whether injections of VRT106 are safe and can help adults aged 18–70 with recurrent or progressive glioblastoma.
-
Intravenous VRT106 for locally advanced or metastatic solid tumors
This Phase 1 trial will test whether an intravenous medicine called VRT106 is safe and tolerable for adults (18–75) with locally advanced or metastatic solid tumors who have run out of standard treatment options.
-
Using a virus to treat solid tumors
This study is testing whether a new virus treatment can safely help people with advanced solid tumors by seeing how well it works and how much can be given.
-
Treatment of advanced solid tumors with intravenous M1-c6v1
This study is testing a new treatment using an oncolytic virus given through an IV to see if it can safely help people with advanced solid tumors.
Quick answers
How many clinical trials run by Guangzhou Virotech Pharmaceutical Co., Ltd. are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in China (5 trials), Japan (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 3, Phase 2: 1, Phase 1/2: 1, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.